Adverum Biotechnologies, Inc. ADVM
We take great care to ensure that the data presented and summarized in this overview for Adverum Biotechnologies, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ADVM
View allLatest Institutional Activity in ADVM
Top Purchases
Top Sells
About ADVM
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Insider Transactions at ADVM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 30
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
85,800
+3.65%
|
$600,600
$7.15 P/Share
|
|
Jul 18
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
80,718
+3.57%
|
$726,462
$9.11 P/Share
|
|
Jul 17
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
135,546
+6.06%
|
$948,822
$7.75 P/Share
|
|
Feb 07
2024
|
Lupher, Jr. Mark L. |
BUY
Open market or private purchase
|
Direct |
130,000
+50.0%
|
$130,000
$1.35 P/Share
|
|
Feb 07
2024
|
James Paul Scopa |
BUY
Open market or private purchase
|
Direct |
100,000
+50.0%
|
$100,000
$1.35 P/Share
|
|
Sep 15
2023
|
Setareh Seyedkazemi CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
6,201
-5.77%
|
$6,201
$1.54 P/Share
|
|
Jun 07
2023
|
Linda M Rubinstein CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
100,000
+50.0%
|
$100,000
$1.45 P/Share
|
|
Mar 15
2023
|
Laurent Fischer CEO, PRESIDENT AND DIRECTOR |
SELL
Open market or private sale
|
Direct |
41,239
-5.62%
|
$0
$0.78 P/Share
|
|
Mar 15
2023
|
Peter Soparkar CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
13,360
-4.78%
|
$0
$0.78 P/Share
|
|
Mar 15
2023
|
Brigit Riley Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,299
-5.85%
|
$0
$0.78 P/Share
|
|
Sep 19
2022
|
Richard Beckman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,272
-9.86%
|
$4,272
$1.07 P/Share
|
|
Sep 19
2022
|
Setareh Seyedkazemi CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
6,058
-11.23%
|
$6,058
$1.07 P/Share
|
|
Sep 19
2022
|
Peter Soparkar CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
13,305
-4.64%
|
$13,305
$1.07 P/Share
|
|
Sep 19
2022
|
Brigit Riley Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,266
-5.77%
|
$7,266
$1.07 P/Share
|
|
Sep 19
2022
|
Laurent Fischer CEO, PRESIDENT AND DIRECTOR |
SELL
Open market or private sale
|
Direct |
41,082
-5.35%
|
$41,082
$1.07 P/Share
|
|
Sep 14
2022
|
Richard Beckman Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+41.67%
|
-
|
|
Sep 14
2022
|
Setareh Seyedkazemi CHIEF DEVELOPMENT OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
33,333
+38.2%
|
-
|
|
May 23
2022
|
Setareh Seyedkazemi CHIEF DEVELOPMENT OFFICER |
BUY
Open market or private purchase
|
Direct |
20,000
+49.26%
|
$0
$0.84 P/Share
|
|
May 17
2022
|
Richard Beckman Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$0
$0.82 P/Share
|
|
May 17
2022
|
Rupert D'Souza Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+32.41%
|
$0
$0.83 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 532K shares |
|---|